Vaccine Candidate Fast-Tracked Against Staphylococcus aureus

LimmaTech Biologics AG announced today that the U.S. Food and Drug Administration had granted Fast Track designation to the company's multivalent toxoid vaccine candidate, LBT-SA7.

This innovative vaccine is designed to prevent skin and soft tissue infections (SSTIs) caused by the bacterial pathogen Staphylococcus aureus (S. aureus).

It is estimated that more than 1 million deaths are attributed to S. aureus each year. Notably, 90% of all community-acquired S. aureus infections are SSTIs.

S. aureus has been designated as a "high priority" pathogen by the World Health Organization, highlighting the urgency for innovative vaccine approaches and effective treatment strategies.

Dr. Franz-Werner Haas, CEO of LimmaTech, commented in a press release on December 19, 2024, "Staphylococcus aureus infections are a major cause of global mortality and morbidity, with traditional antibiotic treatments becoming increasingly ineffective due to rising antibiotic resistance."

LBT-SA7 will be tested in a Phase 1 study at a clinical trial center in the U.S., including 130 adult participants, with initial results anticipated in the second half of 2025.